Arcturus posts Phase 1/2 results for ARCT-2304 self-amplifying mRNA flu vaccine
Arcturus Therapeutics reported completed results for its H5N1 pandemic influenza vaccine candidate ARCT-2304 in a dose- and schedule-finding study in healthy adults.
Arcturus Therapeutics had one trial update posted this week involving its self-amplifying mRNA pandemic influenza vaccine candidate.
- ARCT-2304, a Phase 1/2 self-amplifying mRNA pandemic influenza vaccine, completed its study with results posted. The trial was a first-in-human, randomized, controlled, observer blind, dose level and schedule-finding study evaluating safety, reactogenicity, and immunogenicity of the H5N1 vaccine as a 2-dose series compared with an inactivated influenza vaccine.1 The study enrolled 212 participants1 and was sponsored by Arcturus Therapeutics with the Biomedical Advanced Research and Development Authority listed as a collaborator.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.